Overview

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Vortioxetine